A neuroprotective drug improved recovery after ischemic stroke in a Chinese trial

An experimental drug meant to protect brain tissue after a stroke improved patients' recovery in a large trial in China, one of the few positive results in a research area defined by decades of failure. In the LAIS trial, published in JAMA, 69.7% of patients given intravenous loberamisal had little or no disability 90 days after an acute ischemic stroke, against 56.3% of those given placebo — a 13-percentage-point difference on top of standard care [s1].

The result is notable mainly because so many drugs like it have not worked. Neuroprotection — shielding neurons from the cascade of damage that follows a blocked artery, rather than reopening the artery itself — has been one of stroke medicine's longest-running disappointments, with a string of compounds that looked promising in the laboratory and then failed in patients [s1]. Loberamisal is a small molecule that acts on two targets at once: the PSD-95 scaffolding protein, part of the machinery through which over-excited neurons kill themselves, and a subtype of the GABA-A receptor that dampens neuronal firing [s1].

What the trial found

LAIS was a double-blind, placebo-controlled phase 3 trial at 32 hospitals in China [s1][s2]. It enrolled 998 adults aged 18 to 80 with an acute ischemic stroke of moderate severity — a National Institutes of Health Stroke Scale score of 7 to 20 — and no meaningful disability beforehand, treated within 48 hours of symptom onset between July and December 2024 [s1]. Participants were randomly assigned to intravenous loberamisal, 40 mg once daily for 10 days, or matching placebo, added to standard stroke care [s1]. The primary outcome was a full functional recovery at 90 days, defined as a score of 0 or 1 on the modified Rankin Scale, the standard 0-to-6 measure of post-stroke disability [s1].

Among the 997 patients analysed, 350 of 502 on loberamisal (69.7%) reached that outcome, versus 279 of 495 on placebo (56.3%) — a relative risk of 1.24 (95% confidence interval, 1.12 to 1.36) and an absolute difference of 13.28 percentage points (7.24 to 19.32) [s1]. Safety looked reassuring: serious adverse events occurred in 8.6% of the loberamisal group and 10.7% of the placebo group, and all-cause deaths in 1.2% versus 2.0% [s1]. The confidence interval on the benefit does not cross the line of no effect, so within this trial the result is statistically robust [s1].

What it does and does not establish

The caveats are about generalisability and confirmation, not internal validity. The trial was conducted entirely in China, in a health system whose acute-stroke pathways — including how many patients also received clot-busting drugs or mechanical clot removal — may differ from those elsewhere, and the drug's effect on top of modern reperfusion treatment is the question that matters most for high-income practice [s1]. A single positive phase 3 trial, however clean, is where a neuroprotectant's story should get more sceptical, not less: this field's graveyard is full of agents that succeeded once and could not be reproduced, and the authors themselves call for further studies to validate the finding and test whether it extends to a broader population [s1].

The 48-hour treatment window is unusually wide for an acute stroke drug and, if it holds up, would be practically valuable, since it does not demand the near-immediate treatment that reperfusion therapies require [s1]. But that same width invites scrutiny of exactly when and in whom the benefit arises, detail that a confirmatory trial in a different setting would need to pin down.

For now, loberamisal is a genuinely promising signal in a domain that has produced very few — a well-conducted, adequately sized trial with a significant result on a hard clinical endpoint, awaiting the independent replication that separates a real stroke therapy from another false dawn. It arrives as stroke care is being reshaped more by faster imaging and treatment pathways and by global efforts to widen access to acute care than by drugs. This article describes trial findings and is not medical advice.

Sources

• Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial — JAMA, published online 10 September 2026
• LAIS trial registration (NCT06517173) — ClinicalTrials.gov